Role of coagulation disorders in mesenteric ischemia;Place des anomalies de la coagulation dans l'ischemie mesenterique

Journal de Chirurgie

Volumn 133, Issue 9-10, 1996, Pages 442-447

  Maloisel, F ^a  

^a HÔPITAL DE HAUTEPIERRE   (France)

Author keywords

inherited thrombophilia; ischemic bowel disease; mesenteric thrombosis

Indexed keywords

ACTIVATED PROTEIN C;

BLOOD CLOTTING; HUMAN; MESENTERIC VEIN THROMBOSIS; REVIEW; THROMBOEMBOLISM; THROMBOPHILIA;

ADULT; ANTIPHOSPHOLIPID SYNDROME; ANTITHROMBIN III DEFICIENCY; BLOOD COAGULATION DISORDERS; COLITIS, ISCHEMIC; HUMANS; INTESTINES; ISCHEMIA; MESENTERIC ARTERIES; MESENTERIC VASCULAR OCCLUSION; MESENTERIC VEINS; MIDDLE AGED; PROTEIN C; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY;

EID: 0030427183     PISSN: 00217697     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Bovill EG, Bauer KA, Dickermann JD, Callas P, West B. The clinical spectrum of heterozygous protein C deficiency in a large New England kindred. Blood 1989 ; 73 : 712.
2. Conard J. Résistance à la protéine C activée. M/T 1995 ; 1 : 828-33.
3. Conard J, Cazenave B, Horellou MH, Samama M. Déficit congénitaux en antithrombine III. A propos de 7 familles. Med Hyg 1981 ; 39 : 4259-66.
4. Dahlbäck B. Inherited thrombophilia : resisance to activated protein C as a pathogenic factor of venous thromboenbolism. Blood 1995 ; 85 : 607-14.
5. Dahlbäck B, Carlsson M, Svensson PJ : Familial thrombophilia due to a previous unrecognized mechanism characterized by poor anticoagulant response to activated protein C : Prediction of a cofactor to activated protein C. Proc Natl Acatl Sci USA 1993 ; 90 : 1004.
6. Dahlback B, Hillarp A, Rosen S, Zoller B. Resistance to activated protein C, the FV : Q506 allele, and venous thrombosis. Ann Hematol 1996 ; 72 : 166-176.
7. Dahlbäck B, Stenflo J. The protein C anticoagulant system, in Stamatoyannopoulos G, Nienhuis AW, Majerus PW, Varmus H (eds) : The molecular basis of blood diseases. Philadelphia PA, Saunders, 1994 ; 599.
8. Engesser L, Broekmans AW, Briët E, Brommer EJP, Bertina RM, Hereditary protein S deficiency : clinical manifestations. Ann Intern Med 1987 ; 106 : 677-82.
9. Esmon CT, Schwaarz HP. An update on clinical and basic aspects of the protein C anticoagulant pathway. Trends Cardiovasc Med 1995 ; 5 : 141-8.
10. Ginsberg JS. Increased thrombin generation and activity in patients with systemic lupus erythematosus and anticardiolipin antibodies : evidence for a prothrombotic state. Blood 1993 ; 81 : 2958-63.
11. Gladson CL, Scharrer I, Hach V, Beck KH, Griffin JH. The frequency of type I heterozygous protein S and protein C deficiency in 141 unrelated young patients with venous thrombosis. Thromb Haemost 1988 ; 59 : 18-22.
12. Heijboer H, Brandjes D, Büller HR, Sturk A, ten Cate JW. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Eng J Med 1990 ; 323 : 1512-6.
13. Heijer MD, Koster T, Blom HJ et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996 ; 334 : 759-62.
14. Ireland H et al. Factor V Leiden as an independent risk factor for thrombosis in antithrombin deficiency type II : heparin binding site. Thromb Haemost 1995 ; 73 : 1361.
15. Kœleman BPC, Reitsma PH, Allart CF, Bertina RM : Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood 1994 ; 84 : 1031-5.
16. Manucci PM, Boyer C, Wolf M, Tripodi A, Larrieu MJ. Treatment of congenital antithrombin III deficiency with concentrates. Br J Haematol 1982 ; 50 : 531-5.
17. Roubey RAS : Autoantibodies to phospholipid-binding plasma proteins : a new view of lupus anticoagulants a nd other «antiphospholipid» antibodies. Blood 1994 ; 84 : 2854-67.
18. 50, 3-1987, 16 p.
19. Sholar PW, Bell WR. Thrombolytic therapy for inferior vena cava thrombosis in paroxysmal noctural hemoglobinuria. Ann Intern Med 1985 ; 103 : 539-41.
20. Soria J, Soria C, Caen JP. A new type of congenital dysfibrinogenemia with defective fibrin lysis : Dusard syndrome possible relation of thrombosis. Br J Haematol 1983 ; 53 : 575-86.
21. Soubrier F, Fery I, Verdy E, René MN, Varsat B, Visvikis S, Siest G. The frequency of the factor V gene R506Q mutation varies between regions of France. Nouv Rev Fr Hematol 1995 ; 37 : 175.
22. Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994 ; 330: 517-22.
23. Tabernero MD, Tomas JF, Alberca I, Orfao A, Borrasca AL, Vicente V : Incidence and clinical characteristics of hereditary disorders associated with venous thrombosis. Am J Hematol 1991 ; 36 : 249-54.
24. Valla D, Casadevall N, Lacombe C et al. Primary myeloproliferative disorder and hepatic vein thrombosis. A prospective study of colony formation in vitro in 20 patients with Budd Chiari syndrome. Ann Intern Med 1985 ; 103 : 329-34.
25. Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994 ; 344 : 1453-7.
26. Voorberg J, Roelse J, Koopman R, Büller H, Berends F, Ten Cate JW, Mertens K, Van Mourik JA : Association of idiopathic thromboembolism with single point mutation at Arg 506 of factor V. Lancet 1994 ; 343 : 1535-6.
27. Zoller B, Berntsdotter A, Garcia de Frutos P, Dahlbäck B. Resistance to activated protein C as an additional genetic risk factor to hereditary deficiency of protein S. Blood 1995 ; 85 : 3518-23.